Why Concentration Data Alone Is Not Enough
A bioanalytical study produces concentration-time data: measurements of drug (and sometimes metabolite) levels in biological matrices at defined timepoints. That data is necessary, but on its own it does not answer the questions that matter for drug development. How does exposure change with dose? What is the relationship between exposure and effect? What dose is needed to achieve the target concentration in the intended patient population? How often does the drug need to be dosed to maintain effective concentrations?
Pharmacokinetic (PK) and pharmacodynamic (PD) modelling provides the framework for answering those questions. PK modelling describes how the body handles the drug over time: absorption, distribution, metabolism, and excretion. PD modelling describes the relationship between drug exposure and biological effect. Together, PK/PD modelling transforms concentration data into the quantitative understanding needed to make dose selection and clinical trial design decisions with confidence.
The PK Parameters That Drive Drug Development Decisions
| PK Parameter | Definition | Why It Matters |
| AUC (area under the curve) | Total drug exposure over a defined time period | Primary measure of systemic exposure; used to assess dose proportionality and accumulation |
| Cmax | Peak plasma concentration after a dose | Related to acute tolerability and, for some drugs, to efficacy and toxicity thresholds |
| Tmax | Time to peak concentration | Reflects rate of absorption; relevant to onset of effect |
| t1/2 (elimination half-life) | Time for drug concentration to halve during the elimination phase | Determines dosing interval and time to steady state (approximately 5 x t1/2) |
| CL (clearance) | Volume of plasma cleared of drug per unit time | Determines the dose required to achieve a target steady-state exposure |
| Vd (volume of distribution) | Apparent volume in which the drug distributes | High Vd indicates extensive tissue distribution; affects loading dose requirements |
| Bioavailability (F) | Fraction of dose reaching systemic circulation | Critical for oral and other non-intravenous routes; determines dose needed for a given exposure target |
Non-Compartmental vs. Compartmental Analysis
Non-Compartmental Analysis (NCA)
Non-compartmental analysis is the standard approach for summarising PK data from individual studies. It makes no assumptions about the underlying PK model and derives parameters such as AUC, Cmax, t1/2, and clearance directly from the observed concentration-time data using trapezoidal integration and regression. NCA is used to characterise PK in each arm of a clinical study and to assess dose proportionality across dose levels.
Population PK Modelling
Population PK modelling uses a mixed-effects approach to simultaneously analyse PK data from all subjects in a study, or across multiple studies, and to identify covariates, such as body weight, renal function, or hepatic function, that explain variability in drug exposure between individuals. Population PK models are increasingly required as part of the regulatory submission package. The FDA’s guidance on population pharmacokinetics describes the expectations for population PK analysis in NDA and BLA submissions.
PK/PD Modelling for Dose Selection
PK/PD modelling links drug exposure to a pharmacodynamic effect, whether a biomarker response, a clinical outcome, or a safety signal, through a mathematical relationship. The most commonly used models for concentration-effect relationships are the Emax model and its variants, which describe the sigmoidal relationship between drug concentration and effect with parameters including the maximum effect (Emax), the concentration producing 50% of maximum effect (EC50), and the Hill coefficient describing the steepness of the relationship.
Building a PK Study Package That Answers Regulatory Questions
A well-structured PK programme in early clinical development generates the data needed to make dose selection decisions for subsequent studies and to address the PK questions that will arise in regulatory review. Key components of an early clinical PK package include a single ascending dose study, a multiple ascending dose study, and often a food effect study for oral products.
The FDA’s M3(R2) guideline on non-clinical safety studies and the EMA’s guidance on first-in-human studies both address the PK characterisation expected before clinical dose escalation, and the FDA’s clinical pharmacology guidance documents set out the expectations for the PK data package supporting NDA submissions. Designing a study programme with the regulatory endpoint in mind from the outset avoids the need for additional studies to fill data gaps at the time of submission.
Ardena’s PK/PD Services at Assen
Ardena’s bioanalytical team in Assen provides the sample analysis services that generate the concentration-time data underpinning PK/PD programmes, using validated LC-MS/MS and ligand-binding assay methods. The team supports NCA reporting and works with clinical pharmacology partners to provide the bioanalytical component of population PK and PK/PD analyses.
Integrated PK and immunogenicity data from the same study is a particular capability: understanding whether elevated or reduced drug exposure in a subset of subjects is linked to ADA development is a question that requires both datasets to be available and interpreted in parallel.
